

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1.-8. (canceled).**

**9. (currently amended):** A method for measuring an occupying ratio of a compound bound to a strong binding site of CCR5 on a CCR5 expressing cell or a membrane fraction thereof, which comprises

(a) allowing a CCR5 expressing cell or a membrane fraction thereof to contact with a compound to be tested,

(b) allowing the test compound-bound cell or a membrane fraction thereof prepared in the above step (a) to contact with a labeled anti-CCR5 antibody, wherein when an antagonist or an agonist is bound to the strong binding site of CCR5, the antibody has a property of not binding to CCR5, or an isotype control of the labeled anti-CCR5 antibody, and

(c) calculating an occupying ratio of the compound bound to the strong binding site of CCR5 on the cell or membrane fraction thereof, based on the ratio of:

\_\_\_\_\_a bound amount of the anti-CCR5 antibody when the compound is bound to CCR5 corrected by using the isotype control to

\_\_\_\_\_a bound amount of the anti-CCR5 antibody when the compound is not bound to CCR5 corrected by using the isotype control, which is defined as 100%.

**10.-32 (canceled).**

33. (new): The method according to claim 9, wherein the anti-CCR5 antibody is 45531.111 antibody and/or 45523.111 antibody.